Compound guide · Tier C
CJC-1295
Two different molecules are sold under one name. The human data that exists measures a hormone level, not an outcome, and development stopped.
The short answer
CJC-1295 has more human data behind it than most of this catalogue and less than its reputation suggests. Early phase studies in healthy adults established that it raises growth hormone and IGF-1, and does so for a long time in the DAC form. That is a pharmacodynamic finding. No controlled trial has shown that the resulting hormone elevation produces a clinical benefit in body composition, recovery or anything else, and the development programme did not continue to the trials that would have answered that. Buying it means accepting a biomarker as a proxy for a result, which is exactly the substitution this site exists to point out.
At a glance
| Class | Growth hormone releasing hormone (GHRH) analogue |
| Developer | ConjuChem Biotechnologies |
| Sold as | None. Sold as research material in two forms, with and without DAC. |
| Regulatory status | Not approved by any regulator. Development was discontinued. As of April 2026 CJC-1295 remains on the FDA 503A Category 2 bulk substances list, meaning it cannot lawfully be compounded under 503A and that the agency considers the safety questions unresolved, with cardiac adverse event signals among the grounds cited. |
| Compounding status | Like ipamorelin, and unlike BPC-157, TB-500 and GHK-Cu, CJC-1295 was not removed from the 503A Category 2 list in the April 2026 revision. Anyone citing that revision as evidence that peptides have been cleared should check which compounds it actually covered. |
| Anti-doping | Prohibited at all times under S2 as a growth hormone releasing factor. |
| Our evidence tier | Tier C. Weak human data |
What it is
CJC-1295 is a modified fragment of growth hormone releasing hormone. It is sold in two forms and they are not interchangeable. The version with DAC carries a drug affinity complex, a maleimide group that binds serum albumin and extends the half life from minutes to days, producing a sustained elevation of growth hormone and IGF-1. The version without DAC is a modified GHRH fragment with a short half life, essentially the peptide also sold as modified GRF (1-29). A vendor page that does not tell you which one you are buying is not describing the same product twice.
Who it is for, and who actually takes it
There is no approved population. The published human work was conducted in healthy adult volunteers in early phase studies designed to characterise the hormone response and the safety profile, not to treat anyone.
It is bought for body composition, recovery and sleep, most often paired with ipamorelin on the theory that a GHRH analogue plus a ghrelin receptor agonist produce a larger combined pulse. That combination has not been tested in a controlled human trial for any of those outcomes.
What the research shows
The human data for CJC-1295 is a hormone concentration curve in healthy volunteers, not an outcome. Charting it beside our weight change and adverse event charts would give a biomarker the visual weight of a result, which is the exact error this page is about.
Dosing
We report only what published research used. The early phase human studies of CJC-1295 with DAC administered single and multiple subcutaneous doses to healthy volunteers and measured growth hormone and IGF-1 over the following days, and the sustained elevation observed is the origin of the weekly framing found on vendor sites. Those are research parameters from a discontinued programme, recorded for what they are. They are not a protocol and they establish no benefit. We publish no schedule and no reconstitution guidance.
What happens when you come off it
Growth hormone and IGF-1 return toward baseline once the compound clears, which for the DAC form takes considerably longer than for the version without it. There is no controlled human evidence of any persisting effect after discontinuation, because there is no controlled human evidence of a clinical effect during administration either.
What it is being studied for
| Area | Stage of evidence |
|---|---|
| Growth hormone and IGF-1 elevation in healthy adults | Early phase human data, biomarker endpoint |
| Sustained release pharmacology of the DAC form | Characterised in early phase studies |
| Body composition or lean mass | No controlled human trial |
| Recovery, injury or sleep | No controlled human trial |
| Any approved therapeutic indication | None. Development discontinued |
Everything in the human column is a hormone measurement. Nothing in it is an outcome. That is the single most important thing to understand about CJC-1295 before buying it.
Common myths
CJC-1295 is clinically proven because there are published human studies.
The published human studies measured growth hormone and IGF-1 in healthy volunteers. They were designed to characterise pharmacology, not to demonstrate benefit, and no later trial established one. A published study is not the same as a positive outcome trial.
With DAC and without DAC are the same peptide at different prices.
They are pharmacologically different. The DAC form binds albumin and acts over days. The form without DAC clears in minutes to hours. The price difference on the vendor page reflects a real difference in the molecule, and the research they each point to is not interchangeable.
Stacking it with ipamorelin is the studied protocol.
There is no controlled human trial of the combination. The stack is a community practice built on the mechanistic argument that the two act on different receptors. That argument is coherent and it is not evidence.
More growth hormone is straightforwardly good.
Growth hormone excess is a recognised disease state, acromegaly, and IGF-1 elevation is not a benefit in itself. The FDA kept CJC-1295 on its Category 2 compounding list in April 2026 on safety grounds including cardiac signals.
Verifying a purchase
The critical check on CJC-1295 is which molecule you actually received. The DAC and non DAC forms have clearly different masses, so a mass spectrometry report resolves the question immediately and an HPLC purity figure alone does not. Ask for the mass, compare it against the form you paid for, and confirm the report carries the batch code on your vial. Substitution of the cheaper non DAC peptide for the considerably more expensive DAC form is the obvious commercial temptation in this product pair.
The general method is set out in our guide to reading a certificate of analysis, which covers the eleven checks that apply to any compound. The points above are the ones specific to CJC-1295.
Caveats and safety
The FDA has cited cardiac related adverse event signals in keeping CJC-1295 in Category 2. Sustained elevation of growth hormone and IGF-1, which is precisely what the DAC form is designed to produce, carries the theoretical concern about promoting growth of existing malignancy, and affects glucose handling. Long term human safety data does not exist for either form.
Where to get it
Where to get it
CertaPeptides Romania, EU. Volume discounts at 3+, 5+ and 10+ units. The DAC and non DAC forms are separate products at separate prices.
| Vial | Price |
|---|---|
| 2 mg, without DAC | €29.99 |
| 5 mg, without DAC | €47.99 |
| 10 mg, without DAC | €71.99 |
| With DAC, separate product | from €85.99 |
Stated purity. ≥98% stated batch specification. Published lot report #212158 returned 99.09% on a 2 mg vial without DAC, with 1.92 mg measured against a 2 mg label. The DAC form is listed and priced separately, and its report should be checked separately.
Documentation. Selected lots independently tested by Janoshik Analytical (Czech Republic), HPLC plus mass spectrometry, reports searchable on the Janoshik public portal and at certapeptides.com/verify.
CJC-1295 is sold as laboratory research material. The vendor states it is not for human consumption and that it is not approved by the FDA, the EMA or any other regulator for use in humans or animals. Read the evidence tier at the top of this page before the price.
View CJC-1295 at CertaPeptidesAffiliate link. We earn a commission if you buy, at no extra cost to you. It does not change a word of the assessment above. Every product we have priced, in one list.
Sources
- FDA bulk drug substances nominated for use under section 503A
- WADA Prohibited List, section S2
- CJC-1295 literature, PubMed
- Registered CJC-1295 trials, ClinicalTrials.gov
Related compounds
Disclosure. PeptoPurity is an affiliate of CertaPeptides and earns a commission on qualifying purchases made through the vendor link on this page, at no additional cost to you. That relationship does not set the evidence tier, alter the verdict, or change a word of the assessment. Our Tier C and Tier D pages carry the same links as our Tier A pages, with the same conclusions we would publish if we earned nothing. Where the registered, prescribed route is the better option, we say so on the page that would otherwise pay us.
Scope. This is an evidence review, not medical advice. Where an approved label schedule is reproduced it is a record of what a regulator has published about a licensed medicine, not a recommendation and not a schedule for anyone to follow unsupervised. For unapproved compounds we report only the doses used in published studies, attributed to those studies, and we publish no protocols and no reconstitution guidance for any compound. Regulatory status differs between countries and changes over time. Material sold for laboratory research is not approved for human use. Decisions about treatment belong with a qualified prescriber.